Clinical Trial Update: Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JCAR015 in adult B-cell acute lymphoblastic leukemia has been terminated; results are posted but no efficacy conclusions are provided…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• JCAR015

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-07-19